For instance, serous borderline tumors or low-grade serous ovarian carcinoma (LGSOC) are characterized by frequent KRAS or BRAF mutations while mucinous tumors carry KRAS mutations and endometrioid ovarian tumors harbor PTEN mutations [3]. This evidence concerns the gene KRAS and mucinous neoplasm.